Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - von willebrand factor, quantity: 1200 iu; factor viii, quantity: 500 iu - injection, diluent for - excipient ingredients: - the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. the prophylaxis and treatment of non-surgical and surgical bleeding associated with factor viii deficiency due to haemophilia a.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 250 iu; von willebrand factor, quantity: 600 iu - injection, diluent for - excipient ingredients: - the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. the prophylaxis and treatment of non-surgical and surgical bleeding associated with factor viii deficiency due to haemophilia a.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - von willebrand factor, quantity: 1000 iu; factor viii, quantity: 500 iu - injection, solution - excipient ingredients: water for injections - aleviate is indicated for: ? the treatment of bleeding episodes including surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. ? the treatment and prophylaxis of bleeding associated with factor fviii deficiency due to haemophilia a.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 250 iu; von willebrand factor, quantity: 500 iu - injection, solution - excipient ingredients: water for injections - aleviate is indicated for: ? the treatment of bleeding episodes including surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. ? the treatment and prophylaxis of bleeding associated with factor fviii deficiency due to haemophilia a.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - iron sucrose, quantity: 540 mg/ml (equivalent: iron, qty 20 mg/ml) - injection, concentrated - excipient ingredients: sodium hydroxide; water for injections - venofer is indicated for the treatment of iron deficiency anaemia in patients undergoing chronic haemodialysis and who are receiving supplemental erythropoietin therapy.,the diagnosis of iron deficiency must be based on appropriate laboratory tests (e.g. serum ferritin, serum iron, transferrin saturation and hypochromic red cells).

Malaysia - Inggeris - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

poh lin brand products agency sdn. bhd. - semen euryale ferox salisb; rhizoma ligusticum chuanxiong.; rhizoma dioscorea opposita; radix paeonia lactiflora; radix morinda officinalis; radix codonopsis pilosula; radix astragalus membranaceus; radix angelica sinensis; poria cocos.; herba epimedium sagittatum.; fructus lycium barbarum; cortex eucommia ulmoides.; radix panax ginsen; rhizoma atractylodes macrocephala; radix polygonum multiflorum; honey; rhizoma cibotium barometz -

Kanada - Inggeris - Health Canada

pharmascience inc - iron (iron sucrose) - solution - 20mg - iron (iron sucrose) 20mg - iron preparations

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - von willebrand factor, quantity: 500 iu; factor viii, quantity: 250 iu - injection, powder for - excipient ingredients: albumin; sodium chloride; calcium chloride dihydrate; plasma proteins; sodium citrate dihydrate; sucrose; trometamol - biostate is indicated for: - the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin, (ddavp) treatment is ineffective or contraindicated. - the prophylaxis and treatment of non-surgical and surgical bleeding associated with fviii deficiency due to haemophilia a.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 500 iu; von willebrand factor, quantity: 1000 iu - injection, powder for - excipient ingredients: albumin; plasma proteins; calcium chloride dihydrate; sodium chloride; sodium citrate dihydrate; sucrose; trometamol - biostate? is indicated for: - the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin, (ddavp) treatment is ineffective or contraindicated. - the prophylaxis and treatment of non-surgical and surgical bleeding associated with fviii deficiency due to haemophilia a.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 250 iu; von willebrand factor, quantity: 500 iu - injection, powder for - excipient ingredients: albumin; calcium chloride dihydrate; plasma proteins; sodium chloride; sodium citrate dihydrate; sucrose; trometamol - ?tbsf? high purity factor viii / von willebrand factor concentrate is indicated for: - the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. - the prophylaxis and treatment of non-surgical and surgical bleeding associated with fviii deficiency due to haemophilia a.